Emergent BioSolutions has secured a new supply agreement with the British Columbia Provincial Health Services Authority to deliver its NARCAN® Nasal Spray to the province’s expanded Take‑Home Naloxone Program. The partnership will provide the drug to tens of thousands of residents through community sites, pharmacies, and First Nations institutions, positioning Emergent as the primary supplier for a major public‑health initiative in Canada.
The deal follows a $18 million CAD investment by the B.C. government to broaden access to nasal naloxone. The expanded program, which has been in place since 2012, will now reach additional community sites and First Nations communities, building on a 2024 pilot that distributed 60,000 kits.
Emergent’s Q4 2025 earnings report showed a net loss of $54.6 million on revenues of $148.7 million, missing analyst expectations of $237 million. The company highlighted progress in its multi‑year turnaround strategy, noting improved operating margins and a strong adjusted EBITDA of $205 million, as reported by CEO Joe Papa.
Senior Vice President Paul Williams said, 'We applaud the B.C. Ministry of Health for their efforts to make nasal naloxone available to communities across B.C.' The partnership aligns with Emergent’s broader strategy to expand its naloxone portfolio through government and public‑health collaborations.
By securing this contract, Emergent strengthens its presence in the Canadian market and reinforces its leadership in the opioid overdose reversal segment. The deal is expected to enhance the company’s market share in Canada’s naloxone market and support its goal of expanding its commercial footprint beyond the United States.
NARCAN® Nasal Spray has been available at no cost in several other Canadian provinces and territories, and Emergent has supplied the product across Canada and the U.S. since 2016. While the specific dollar value of the supply agreement remains undisclosed, the partnership represents a significant revenue opportunity for Emergent, especially as the province’s funding beyond March 2027 remains uncertain.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.